Notably, the top candidate drug, MW-STK33-97, was previously identified by us as one of the leading compounds capable of neutralizing a detrimental gene program in macrophages exposed to the macroenvironment of acute myocardial infarction patients (38). This evidence concerns the gene STK33 and myocardial infarction.